Co-morbidity and drug treatment in Alzheimer's disease. A cross sectional study of participants in the Dementia Study in Northern Norway
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Inappropriate medical treatment of co-morbidities in Alzheimer's disease (AD) is an increasing concern in geriatric medicine. The objective of this study was to compare current drug use related to co-morbidity between individuals with a recent diagnosis of AD and a cognitively healthy control group in a population based clinical trial in Northern Norway. SETTING: Nine rural municipalities with 70,000 inhabitants in Northern Norway. PARTICIPANTS: PARTICIPANTS with and without AD recruited in general practice and by population based screening.187 participants with a recent diagnosis of AD were recruited among community dwellers. Of 791 respondents without cognitive symptoms, 500 were randomly selected and invited to further clinical and cognitive testing. The final control group consisted of 200 cognitively healthy individuals from the same municipalities. Demographic characteristics, data on medical history and current medication were included, and a physical and cognitive examination was performed. The statistical analyses were carried out by independent sample t-test, chi-square, ANCOVA and logistic regression. RESULTS: A co-morbidity score was significantly higher in AD participants compared to controls. The mean number of drugs was higher for AD participants compared to controls (5.1±3.6 and 2.9±2.4 respectively, p<0.001 age and gender adjusted), also when adjusted for co-morbidity. AD participants used significantly more anticholinergic, sedative and antidepressant drugs. For nursing home residents with AD the mean number of drugs was significantly higher compared to AD participants living at home (6.9±3.9 and 4.5±3.3, respectively, p<0.001). CONCLUSIONS: AD participants were treated with a significantly higher number of drugs as compared to cognitively healthy controls, even after adjustment for co-morbidity. An inappropriate use of anticholinergic and sedative drugs was identified, especially among nursing home residents with AD. The drug burden and the increased risk of adverse reactions among individuals suffering from AD need more attention from prescribing doctors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of Dementia in the United States: The Aging, Demographics, and Memory Study
Plassman, B. L., Langa, K. M., Fisher, G. G., Heeringa, S. G., Weir, D. R., Ofstedal, M. B., Burke, J. R., Hurd, M. D., Potter, G. G., Rodgers, W. L., et al. (2007) · Neuroepidemiology · doi:10.1159/000109998 · Cited by 1,932 · cited 1×
“In particular, this is true for Alzheimer’s disease (AD), constituting 65 - 70% of all dementia subtypes, inflicting an extensive and serious impact on activities of daily living and quality of life for patients and their caregivers [1-5].”
Backgroundvan Beek, A. H., Claassen, J. A., Rikkert, M. G. O., & Jansen, R. W. (2008) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2008.13 · Cited by 485 · cited 1×
“Midlife hypertension may generate arteriosclerosis, cerebral small-vessel disease and disturbed cerebral autoregulation in resistant arteries [35-37], leaving elderly AD individuals prone to cerebral hypoperfusion and cognitive worsening due to extensive antihypertensive treatment [38,39].”
BackgroundThe cognitive impact of anticholinergics: A clinical review
Malaz Boustani, M. (2009) · Clinical Interventions in Aging · doi:10.2147/cia.s5358 · Cited by 479
Prevalence of stress, anxiety and depression in with Alzheimer caregivers
Ferrara, M., Langiano, E., Di Brango, T., De Vito, E., Di Cioccio, L., & Bauco, C. (2008) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-6-93 · Cited by 191
Anticholinergic drug use and risk for dementia: target for dementia prevention
Jessen, F., Kaduszkiewicz, H., Daerr, M., Bickel, H., Pentzek, M., Riedel-Heller, S., Wagner, M., Weyerer, S., Wiese, B., van den Bussche, H., et al. (2010) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-010-0156-4 · Cited by 119 · cited 2×
“Consequently, multiple drug prescriptions are leaving elderly vulnerable to adverse reactions [10-12] and harmful interactions between psychotropic drugs and between psychotropic drugs and drugs aimed to treat co-morbidities, often classified as inappropriate drug prescriptions [13].”
Background
Cited by
Defeating Alzheimer's disease and other dementias: a priority for European science and society
Winblad, B., Amouyel, P., Andrieu, S., Ballard, C., Brayne, C., Brodaty, H., Cedazo-Minguez, A., Dubois, B., Edvardsson, D., Feldman, H., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00062-4 · Cited by 1,676
Agis-Torres, A., Sollhuber, M., Fernandez, M., & Sanchez-Montero, J. M. (2014) · Current Neuropharmacology · doi:10.2174/1570159x113116660047 · Cited by 202
A claims data-based comparison of comorbidity in individuals with and without dementia
Bauer, K., Schwarzkopf, L., Graessel, E., & Holle, R. (2014) · BMC Geriatrics · doi:10.1186/1471-2318-14-10 · Cited by 157
“For our analyses, we included all complexes that had (1) a prevalence of at least 15% within the case or control group of our study population or were (2) accounted for within at least five of the reference studies [5-10,12,16-23] or were (3) considered as being of significant medical interest within a thorough apprai…”
BackgroundMethodde Rooij, A. H. P. M., Luijkx, K. G., Schaafsma, J., Declercq, A. G., Emmerink, P. M. J., & Schols, J. M. G. A. (2012) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2012.02.007 · Cited by 87
Identifying potentially inappropriate prescribing in older people with dementia: a systematic review
Hukins, D., Macleod, U., & Boland, J. W. (2019) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-018-02612-x · Cited by 84
Metadata
- Authors
- Andersen, F., Viitanen, M., Halvorsen, D. S., Straume, B., & Engstad, T. A.
- Venue
- BMC Geriatrics
- Published
- 2011-10-04
- Volume
- 11
- Issue
- 1
- Pages
- 58-58
- ISSN
- 1471-2318 (ISSN-L)
- OpenAlex
- W2144459031
- Cited by
- 71
- References
- 5
- FWCI
- 1.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Co-morbidity and drug treatment in Alzheimer's disease. A cross sectional study of participants in the Dementia Study in Northern Norway. https://app.cochat.ai/papers/10.1186/1471-2318-11-58
- The paper
- Andersen, F., Viitanen, M., Halvorsen, D. S., Straume, B., & Engstad, T. A. (2011). Co-morbidity and drug treatment in Alzheimer's disease. A cross sectional study of participants in the Dementia Study in Northern Norway. BMC Geriatrics. https://doi.org/10.1186/1471-2318-11-58
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.